Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL PLUS versus TAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL PLUS versus TAVIST.
DRIXORAL PLUS vs TAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Category C
Category C
Antihistamine/Decongestant
Antihistamine